By Kara Nyberg, PhD Posted: June 24, 2020 The phase II PASSION trial sought to explore the potential synergy between immunotherapy and antiangiogenic drug therapy previously observed in preclinical studies. […] Read more
Posted: June 24, 2020 Paul G. Kluetz, MD, has been named the FDA’s new Deputy Director of the OCE. During his 10 years with the FDA, Dr. Kluetz founded the […] Read more
By Kara Nyberg, PhD Posted: June 24, 2020 An exploratory analysis of circulating free DNA (cfDNA) shows that lorlatinib confers potent antitumor activity in pretreated patients with ALK-positive NSCLC regardless […] Read more
By Kara Nyberg, PhD Posted: June 24, 2020 Given the variable response to immune checkpoint blockade, researchers have long sought to identify predictive biomarkers beyond PD-L1 to better select patients […] Read more
By Mary Jo Fidler, MD Posted: June 10, 2020 Healthcare systems in the United States have been slow to adopt telehealth, in part, due to regulatory limitations, patient privacy […] Read more
By Narjust Duma, MD Posted: June 10, 2020 During the past 8 weeks, we have heard how many of our colleagues and cancer centers are switching to telehealth. Two things […] Read more
By Brendon Stiles, MD Posted: June 10, 2020 Imagine living in a city with more than 180,000 reported cases of COVID-19 and more than 24,000 deaths. Next imagine asking […] Read more
By Rebecca Matthias, MD Posted: June 10, 2020 Ms. Matthias is a patient with lung cancer who, along with so many, has transitioned to telehealth. Ms. Matthias lives in […] Read more
By Marina Chiara Garassino, MD, and Leora Horn, MD, MSc, FRCPC Posted: June 9, 2020 Marina Chiara Garassino Leora Horn The new SARS-CoV-2 (COVID-19) virus […] Read more
By Joan H. Schiller, MD Posted: August 13, 2020 The COVID-19 pandemic burst upon the world stage with startling force at the beginning of this year. The issues of climate […] Read more